Osteoporosis in the elderly;Ostéoporose chez le sujet âgé

Presse Medicale

Volumn 35, Issue 10 II, 2006, Pages 1547-1556

  Retornaz, Frédérique ^a,b   Duque, Gustavo ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; SEX HORMONE; STRONTIUM RANELATE; VITAMIN D;

ACCIDENT PREVENTION; AGED; COMORBIDITY; DIAGNOSTIC PROCEDURE; FRAIL ELDERLY; HIP; HUMAN; INSTITUTIONAL CARE; OSTEOPOROSIS; PRACTICE GUIDELINE; PROTECTIVE EQUIPMENT; REVIEW; SOCIOECONOMICS; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 33749634259     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74850-3     Document Type: Review

References (78)

1. Becker C, Crow S, Toman J, Lipton C, McMahon DJ, Macaulay W et al. Characteristics of elderly patients admitted to an urban tertiary care hospital with osteoporotic fractures: correlations with risk factors, fracture type, gender and ethnicity. Osteoporos Int. 2006; 17: 410-6.
2. World Health Organisation Assessment of fracture risk and its applications to screening for postmenopausal osteoporosis. WHO technical report series, N843, Geneva: Switzerland World Health Organisation, 1994.
3. Ralston SH. Genetic determinants of osteoporosis. Curr Opin Rheumatol. 2005; 17: 475-9.
4. Eckstein F, Fischbeck M, Kuhn V, Link TM, Priemel M, Lochmuller EM. Determinants and heterogeneity of mechanical competence throughout the thoracolumbar spine of elderly women and men. Bone. 2004; 35: 364-74.
5. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005; 20: 1185-94.
6. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005; 115: 3318-25.
7. Raisz LG, Rodan GA. Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am. 2003; 32: 15-24.
8. Priestwood and Duque. Chapter on osteoporosis. In: Hazzard textbook of medicine 5th edition, chapter 76.
9. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359: 1761-7.
10. Dargent-Molina P. Epidemiology and risk factors for osteoporosis. Rev Med Interne. 2004; 25 Suppl 5: S517-S25.
11. Blain H. Osteoporosis in men: epidemiology, physiopathology, diagnosis, prevention and treatment. Rev Med Interne. 2004; 25 Suppl 5: S552-S9.
12. Wallace RB. Bone health in nursing home residents. JAMA. 2000; 284: 1018-9.
13. Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int. 2006; 17: 565-74.
14. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005; 16 Suppl 2: S3-S7.
15. rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15: 721-39.
16. Baudoin C, Fardellone P, Thelot B, Juvin R, Potard V, Bean K et al. Hip fractures in France: the magnitude and perspective of the problem. Osteoporos Int. 1996; 6 Suppl 3: 1-10.
17. Osteoporosis in Europe: indicators of progress. Report of International Osteoporosis Foundation February 2005. http://www.osteofound.org/ advocacy_policy/ eu_policy_project/pdf/indicators_of_progress.pdf. Consulté le 14.02.06.
18. Maravic M, Le Bihan C, Landais P, Fardellone P. Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int. 2005; 16: 1475-80.
19. Fontana A, Delmas P. L'ostéoporose: épidémiologie, clinigue et approches thérapeutiques. Med Sci (Paris). 2001; 17: 1297-305.
20. No authors listed. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002, 17: 716-24.
21. Grados F, Marcelli C, Dargent-Molina P, Roux C, Vergnol JF, Meunier PJ et al. Prevalence of vertebral fractures in French women older than 75 years from the EPIDOS study. Bone 2004; 34: 362-7.
22. Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 1993; 41: 1226-34.
23. Kelsey JL, Browner WS, Seeley DG, Nevitt MC, Cummings SR. Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group. Am J Epidemiol. 1992; 135: 477-89.
24. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353: 878-82.
25. rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993; 137: 1001-5.
26. Ishida Y, Kawai S, Taguchi T. Factors affecting ambulatory status and survival of patients 90 years and older with hip fractures. Clin Orthop Relat Res. 2005; 208-15.
27. Ismail AA, O'Neill TW, Cooper C, Finn JD, Bhalla AK, Cannata JB et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int. 1998; 8: 291-7.
28. Hasserius R, Karlsson MK, Jonsson B, Redlund-Johnell I, Johnell O. Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly - a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int. 2005; 76: 235-42.
29. Melton LJ 3rd. Excess mortality following vertebral fracture. J Am Geriatr Soc. 2000; 48: 338-9.
30. Kado DM, Duong T, Stone KL, Ensrud KE, Nevitt MC, Greendale GA et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int. 2003; 14: 589-94.
31. Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y et al. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int. 2003; 14: 69-76.
32. rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992; 7: 221-7.
33. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998; 128: 793-800.
34. L'ostéoporose dans la Communauté Européenne: Plan d'Action-Rapport sur les étapes clés d'une Europe exempte de fractures par fragilité. Novembre 2003 http: //www.osteofound.org/ publications/eu_reports.html, consulté le 14/02/06.
35. rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992; 2: 285-9.
36. De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int. 1999; 10: 66-72.
37. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002; 359: 1929-36.
38. Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol. 2006; 194: S12-23.
39. Gregg EW, Pereira MA, Caspersen CJ. Physical activity, falls, and fractures among older adults: a review of the epidemiologic evidence. J Am Geriatr Soc. 2000; 48: 883-93.
40. Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996; 348: 145-9.
41. Retornaz F, Seux V, Reynaud Levy O, Soubeyrand J. La reduction du risgue de chute. Le rhumatologue. 2005; 23: 45-6.
42. Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc. 2004; 52: 1479-86.
43. Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med. 2005; 26: 203-19.
44. Dargent-Molina P, Piault S, Breart G. Identification of women at increased risk of osteoporosis: No need to use different screening tools at different ages. Maturitas. 2005, 6; 54: 55-64.
45. Saliba D, Solomon D, Rubenstein L, Young R, Schnelle J, Roth C et al. Quality indicators for the management of medical conditions in nursing home residents. J Am Med Dir Assoc. 2005; 6: S36-48.
46. Retornaz F, Seux V, Soubeyrand J. Secondary osteoporosis and internal medicine. Rev Med Interne. 2004; 25 Suppl 5: S543-51.
47. Kannus P, Sievanen H, Palvanen M, Jarvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet. 2005; 366: 1885-93.
48. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 2003; 348: 42-9.
49. Liu-Ambrose TY, Khan KM, Eng JJ, Gillies GL, Lord SR, McKay HA. The beneficial effects of group-based exercises on fall risk profile and physical activity persist 1 year postintervention in older women with low bone mass: follow-up after withdrawal of exercise. J Am Geriatr Soc. 2005; 53: 1767-73.
50. Healey F, Monro A, Cockram A, Adams V, Heseltine D. Using targeted risk factor reduction to prevent falls in older in-patients: a randomised controlled trial. Age Ageing. 2004; 33: 390-5.
51. Haines TP, Bennell KL, Osborne RH, Hill KD. Effectiveness of targeted falls prevention programme in subacute hospital setting: randomised controlled trial. BMJ. 2004; 328: 676.
52. van Schoor NM, Asma G, Smit JH, Bouter LM, Lips P. The Amsterdam Hip Protector Study: compliance and determinants of compliance. Osteoporos Int. 2003; 14: 353-9.
53. Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A, Gafni A et al. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2005; 16: 1461-74.
54. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ. 2006; 332: 571-4.
55. de Rooij SE. Hip protectors to prevent femoral fracture. BMJ. 2006; 332: 559-60.
56. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int. 2005; 16: 1425-31.
57. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293: 2257-64.
58. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001; 22: 477-501.
59. Duque G, Macoritto M, Dion N, Ste-Marie LG, Kremer R. 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab. 2005; 288: E723-30.
60. Duque G, Macoritto M, Kremer R. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology. 2004; 5: 421-9.
61. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY et al. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004; 291: 1999-2006.
62. Venning G. Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ. 2005; 330: 524-6.
63. Dhesi JK, Jackson SH, Bearne LM, Moniz C, Hurley MV, Swift CG, Allain TJ. Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing. 2004; 33: 589-95.
64. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr. 2004; 80: 752-8.
65. Ness J, Aronow WS, Newkirk E, McDanel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial. J Gerontol A Biol Sci Med Sci. 2005; 60: 460-2.
66. Meier C, Liu PY, Handelsman DJ, Seibel MJ. Endocrine regulation of bone turnover in men. Clin Endocrinol (Oxf). 2005; 63: 603-16.
67. Simon LS. Osteoporosis. Clin Geriatr Med. 2005; 21: 603-29.
68. Seeman E. Estrogen, androgen, and the pathogenesis of bone fragility in women and men. Curr Osteoporos Rep. 2004; 2: 90-6.
69. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005; 37: 433-40.
70. Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004; 52: 1832-9.
71. Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P et al. FIT Research Group. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res. 2005; 20: 971-6.
72. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344: 333-40.
73. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005; 20: 2105-15.
74. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 1998; 4: 1377-82.
75. Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006; 21: 354-65.
76. Traitement médicamenteux de l'ostéoporose post-ménopausique. Recommandations de l'Agence française de sécurité des produits sanitaires AFSSAPS, Actualisation 2006, www.afssaps.sante.fr
77. Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res. 2006; 21: 536-42.
78. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90: 2816-22.